Back to Authors

Dhesi, Endip

0009-0009-8175-1175

A5035947119 | I4210095227

Mayo Clinic

Eli Lilly (United Kingdom)

Citations 3

P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A129.2-A130

10.1136/gutjnl-2025-bsg.204

P115 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate-to-severe Crohn’s disease: results from phase 3 VIVID 1 study

Poster Presentations | July 1, 2024 | Volume: No volume available | Issue: No issue available | Pages: A120.1-A120

10.1136/gutjnl-2024-bsg.197

P304 Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn’s disease

Poster presentations | June 18, 2023 | Volume: No volume available | Issue: No issue available | Pages: A210.1-A210

10.1136/gutjnl-2023-bsg.370